ALSO NOTED: Botox slowdown doesn't dampen Allergan's Q1; Shandong Lunan launches new API plant

> Allergan more than doubled first-quarter profits to $111 million as strong sales of its eye, skin, and nerve drugs offset lower domestic sales growth of its Botox cosmetic treatment. Report

> Shandong Lunan Pharmaceutical Group wrapped up construction of a new active ingredient plant focused on cephalosporin products, helping push China to the forefront of international 7-ADCA production volume. Report

> FDA asked ZymoGenetics to revise the press release on the launch of its first commercial product, saying that the announcement omitted important facts. Report

> FDA gave the nod to Eli Lilly's Strattera drug for maintenance treatment of ADHD in kids and adolescents. Report

> King Pharmaceuticals posted a year-over-year decline in first quarter revenues from $516 million to $432 million on generic competition for its blood pressure med Altace. Release

> Bentley Pharmaceuticals boosted first-quarter sales by 27 percent to $40 million, with net income of $1.1 million, or 5 cents per share. Release

> Celgene grew revenues by 57 percent in the first quarter, to $461 million, on a 96 percent hike in sales of its Revlimid cancer drug. Release

> Mylan got final FDA approval for its copycat form of the restless legs drug Requip, made by GlaxoSmithKline. Report

> IDM Pharma reported a net loss of $12.1 million on $2.4 million in first-quarter revenues. Report

> Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Enzon report

> Wilex and GPC Biotech are preparing to merge, according to a prominent German newspaper. Report

> Novartis execs are discussing the company's plans in China. China report

And Finally... The first $271 million in facilities grant is just about ready to be doled out by the California stem cell institute. It will trigger more than three-quarters of a billion dollars worth of new construction for the laboratories that are being designed to develop stem cell therapies. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.